ClinicalTrials.gg
Active, not recruitingNCT07344584Updated Aug 13, 2026

A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles in the Cheek Area

An interventional study of GP0122 and GP0124 in Wrinkle Reduction, sponsored by Galderma R&D. Active, not recruiting at 5 sites in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Galderma R&D (part of Galderma Group AG) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the study is to evaluate the safety of GP0122 and GP0124 for the correction of lines and wrinkles in the cheek area.

02

Conditions studied

  • Wrinkle Reduction
03

In context

Lead sponsor

Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Adult males or non-pregnant, non-breastfeeding adult females.

  1. Participants with a GCWS At Rest score of Moderate or Severe on EACH side of the face, or Participants with a CSQS-CL score of Moderate, Severe, or Very severe on EACH side of the face.
  2. Intent to undergo treatment for correction of lines and wrinkles in the cheek region.
  3. Willing to abstain from any other facial plastic, surgical or cosmetic procedures in the cheek area for the duration of the study (e.g., laser or chemical resurfacing, needling, facelift, lifting threads, radiofrequency etc.).

    Inclusion criteria 4-5 apply only to female participants of :

  4. Agrees to use an acceptable form of effective for the duration of the study and is willing to take a urine pregnancy test (UPT) at screening, baseline and prior to receiving any study treatment.
  5. Negative UPT at the screening and baseline visits.

Exclusion Criteria:

  1. Known/previous allergy or .
  2. Known/previous allergy or hypersensitivity to local anesthetics.
  3. Previous facial surgery (e.g., facelift) in the treatment area that in the Treating Investigator´s opinion.
  4. Any previous aesthetic procedures or implants in the treatment area.
  5. Presence of any disease or lesions in the treatment area.
  6. An underlying known disease, a surgical or medical condition that would expose the participant to undue risk.
  7. Use of concomitant medication that have the potential to prolong bleeding times.
  8. Presence of any condition or situation, which in the opinion of the Treating Investigator makes the subject unable to complete the study per protocol.
  9. Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    GP0122

    Participants will receive GP0122 in the cheek area at baseline with an optional touch-up session 1 month after the initial session.

    Device: GP0122

  • Active comparator
    GP0124

    Participants will receive GP0124 in the cheek area at baseline with an optional touch-up session 1 month after the initial session.

    Device: GP0124

Interventions

  • DeviceGP0122

    Injectable gel.

  • DeviceGP0124

    Injectable gel.

06

What researchers measure

Primary outcomes

  1. Number of Participants With all Adverse Events (AEs)

    Time frame: From Day 1 up to last visit (Up to 12 months)

  2. Number of Participants With Post-Treatment Responses as Assessed Using Subject Diary Data

    Time frame: From Day 1 up to Day 28

  3. Participant's Pain Assessment Using Numeric Pain Scale (NPS) Immediately Post Treatment and 30 Minutes Post Treatment

    Time frame: Immediately and 30 minutes after each treatment

Secondary outcomes

  1. Responder Rates Based on the Treating Investigator's Live Assessment of the GCWS at Rest at Months 3, 6, 9 and 12

    Time frame: At Months 3, 6, 9 and 12

  2. Responder Rates Based on the Treating Investigator's Live Assessment of the CSQS-CL at Rest at Months 3, 6, 9 and 12

    Time frame: At Months 3, 6, 9 and 12

07

Study locations

5 sites
  • Galderma Investigational Site #8379
    Burlington, L7N3N2, Canada
  • Galderma Investigational Site #8689
    Toronto, M543N8, Canada
  • Galderma Investigational Site #8688
    Vancouver, V5ZRE1, Canada
  • Galderma Investigational Site #7049
    Vancouver, V6H4E1, Canada
  • Galderma Investigational Site #8162
    Woodbridge, L4L 8E2, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for May 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 15, 2026
StartActual
Feb 17, 2026
Primary completionEst.
May 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07344584
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Feb 17, 2026
Primary completion
May 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion